Shares of INSYS Therapeutics, Inc. (NASDAQ:INSY) dropped -6.02% by the end of trading session at $12.03. For the current quarter, the 4 brokerage firms issuing adjusted earnings per share outlook have a consensus forecast of 0/share, which would compare with $0.36 in the year-ago quarter. The net percentage change is -28.31% over the last 12 months. The trading range in the same period had a highest hit of $21.22 while lowest level was $8.7. At the moment the price is 19.77% above its 50-day moving average and -6.76% below its 200-day moving average.
INSYS Therapeutics, Inc. (NASDAQ:INSY) on February 15, 2017 announced that the Company is providing for the use of Cannabidiol Oral Solution at doses up to 40 mg/kg/day in compassionate use studies in subjects with refractory pediatric epilepsy following completion of 48 weeks of treatment in the ongoing long-term safety study. The long-term safety study permitted subjects who had